Identifying and testing candidate genetic polymorphisms in the irritable bowel syndrome (IBS): Association with TNFSF15 and TNFα

Gut

Volumn 62, Issue 7, 2013, Pages 985-994

  Swan, Caroline ^a   Duroudier, Nathalie P ^a   Campbell, Eugene ^b   Zaitoun, Abed ^c   Hastings, Margaret ^d   Dukes, George E ^e   Cox, Joanne ^e   Kelly, Fiona M ^e   Wilde, Jonathan ^e   Lennon, Mark G ^e   Neal, Keith R ^a   Whorwell, Peter J ^d   Hall, Ian P ^a   Spiller, Robin C ^b  

^a UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^b UNIVERSITY OF NOTTINGHAM   (United Kingdom)

^c NOTTINGHAM UNIVERSITY HOSPITALS NHS TRUST   (United Kingdom)

^d WYTHENSHAWE HOSPITAL   (United Kingdom)

^e GLAXOSMITHKLINE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; EOTAXIN; INTERLEUKIN 10; MESSENGER RNA; MONOCYTE CHEMOTACTIC PROTEIN 4; NUCLEAR RECEPTOR NR1D1; TUMOR NECROSIS FACTOR ALPHA; VASCULAR ENDOTHELIAL GROWTH INHIBITOR;

ADULT; ARTICLE; CALPAIN 8 GENE; CAMPYLOBACTER JEJUNI; CCL11 GENE; CCL13 GENE; CONTROLLED STUDY; CYTOKINE PRODUCTION; DISEASE ASSOCIATION; FEMALE; GABRE GENE; GENE; GENE EXPRESSION; GENE FREQUENCY; GENE FUNCTION; GENE IDENTIFICATION; GENETIC ASSOCIATION; GENETIC POLYMORPHISM; GENOTYPE PHENOTYPE CORRELATION; GPR161 GENE; HUMAN; HUMAN CELL; HUMAN TISSUE; INTERLEUKIN 10 GENE; INTESTINE MUCOSA PERMEABILITY; IRRITABLE COLON; MAJOR CLINICAL STUDY; MALE; NR1D1 GENE; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN DETERMINATION; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; RECTUM BIOPSY; SINGLE NUCLEOTIDE POLYMORPHISM; TNFSF15 GENE; TUMOR NECROSIS FACTOR ALPHA GENE;

COELIAC DISEASE; DIVERTICULAR DISEASE; FUNCTIONAL BOWEL DISORDER; GASTROINTESTINAL MOTILITY; GENETICS; GLUTEN; INFLAMMATORY BOWEL SYNDROME; NEUROGASTROENTEROLOGY; SEROTONIN;

ADULT; CYTOKINES; FEMALE; GENE EXPRESSION PROFILING; GENE EXPRESSION REGULATION; GENE FREQUENCY; GENETIC ASSOCIATION STUDIES; GENETIC PREDISPOSITION TO DISEASE; GENOTYPE; HELICOBACTER INFECTIONS; HELICOBACTER PYLORI; HUMANS; INTESTINAL ABSORPTION; IRRITABLE BOWEL SYNDROME; LEUKOCYTES, MONONUCLEAR; MALE; MIDDLE AGED; OLIGONUCLEOTIDE ARRAY SEQUENCE ANALYSIS; PHENOTYPE; POLYMORPHISM, SINGLE NUCLEOTIDE; RECTUM; TUMOR NECROSIS FACTOR LIGAND SUPERFAMILY MEMBER 15; TUMOR NECROSIS FACTOR-ALPHA;

EID: 84878767661     PISSN: 00175749     EISSN: 14683288     Source Type: Journal    
DOI: 10.1136/gutjnl-2011-301213     Document Type: Article

References (49)

1. Cho JH, Weaver CT. The genetics of inflammatory bowel disease. Gastroenterology 2007;133:1327-39. (Pubitemid 47494470)
2. Barrett JC, Hansoul S, Nicolae DL, et al. Genome-wide association defines more than 30 distinct susceptibility loci for Crohn's disease. Nat Genet 2008;40:955-62.
3. Longstreth GF, Thompson WG, Chey WD, et al. Functional bowel disorders. Gastroenterology 2006;130:1480-91.
4. Saito YA, Mitra N, Mayer EA. Genetic approaches to functional gastrointestinal disorders. Gastroenterology 2010;138:1276-85.
5. Whorwell PJ, McCallum M, Creed F, et al. Non-colonic features of irritable bowel syndrome. Gut 1986;27:37-40. (Pubitemid 16134473)
6. Levy RL, Jones KR, Whitehead WE, et al. Irritable bowel syndrome in twins: heredity and social learning both contribute to etiology. Gastroenterology 2001;121:799-804. (Pubitemid 32959390)
7. Camilleri M, Andrews CN, Bharucha AE, et al. Alterations in expression of p11 and SERT in mucosal biopsy specimens of patients with irritable bowel syndrome. Gastroenterology 2007;132:17-25. (Pubitemid 46108754)
8. Aerssens J, Camilleri M, Talloen W, et al. Alterations in mucosal immunity identified in the colon of patients with irritable bowel syndrome. Clin Gastroenterol Hepatol 2008;6:194-205. (Pubitemid 351172944)
9. Camilleri M, Carlson P, McKinzie S, et al. Genetic susceptibility to inflammation and colonic transit in lower functional gastrointestinal disorders: preliminary analysis. Neurogastroenterol Motil 2011;23:935-e398.
10. Spiller R, Garsed K. Postinfectious irritable bowel syndrome. Gastroenterology 2009;136:1979-88.
11. Dunlop SP, Jenkins D, Neal KR, et al. Relative importance of enterochromaffin cell hyperplasia, anxiety, and depression in postinfectious IBS. Gastroenterology 2003;125:1651-9. (Pubitemid 37500429)
12. Brint EK, Macsharry J, Fanning A, et al. Differential expression of toll-like receptors in patients with irritable bowel syndrome. Am J Gastroenterol 2011;106:329-36.
13. Foley S, Garsed K, Singh G, et al. Impaired uptake of serotonin by platelets from patients with irritable bowel syndrome correlates with duodenal immune activation. Gastroenterology 2011;140:1434-43.e1.
14. Corinaldesi R, Stanghellini V, Cremon C, et al. Effect of mesalazine on mucosal immune biomarkers in irritable bowel syndrome: a randomized controlled proof of concept study. Aliment Pharmacol Ther 2009;30:245-52.
15. Cremon C, Gargano L, Morselli-Labate AM, et al. Mucosal immune activation in irritable bowel syndrome: gender-dependence and association with digestive symptoms. Am J Gastroenterol 2009;104:392-400.
16. Liebregts T, Adam B, Bredack C, et al. Immune activation in patients with irritable bowel syndrome. Gastroenterology 2007;132:913-20. (Pubitemid 46440872)
17. O'Mahony L, McCarthy J, Kelly P, et al. Lactobacillus and bifidobacterium in irritable bowel syndrome: symptom responses and relationship to cytokine profiles. Gastroenterology 2005;128:541-51. (Pubitemid 40585355)
18. Ohman L, Isaksson S, Lindmark AC, et al. T-cell activation in patients with irritable bowel syndrome. Am J Gastroenterol 2009;104:1205-12.
19. Talley NJ, Phillips SF, Melton LJ III, et al. A patient questionnaire to identify bowel disease. Ann Intern Med 1989;111:671-4. (Pubitemid 19259186)
20. Zigmond AS, Snaith RP. The hospital anxiety and depression scale. Acta Psychiatr Scand 1983;67:361-70. (Pubitemid 13098606)
21. Spiller RC, Humes DJ, Campbell E, et al. The Patient Health Questionnaire 12 Somatic Symptom scale as a predictor of symptom severity and consulting behaviour in patients with irritable bowel syndrome and symptomatic diverticular disease. Aliment Pharmacol Ther 2010;32:811-20.
22. Hahn BA, Kirchdoerfer LJ, Fullerton S, et al. Evaluation of a new quality of life questionnaire for patients with irritable bowel syndrome. Aliment Pharmacol Ther 1997;11:547-52. (Pubitemid 27286957)
23. Jenkins D, Balsitis M, Gallivan S, et al. Guidelines for the initial biopsy diagnosis of suspected chronic idiopathic inflammatory bowel disease. The British Society of Gastroenterology Initiative. J Clin Pathol 1997;50:93-105. (Pubitemid 27093023)
24. Rainen L, Oelmueller U, Jurgensen S, et al. Stabilization of mRNA expression in whole blood samples. Clin Chem 2002;48:1883-90.
25. van der Veek PP, van den BM, de Kroon YE, et al. Role of tumor necrosis factor-alpha and interleukin-10 gene polymorphisms in irritable bowel syndrome. Am J Gastroenterol 2005;100:2510-16.
26. Gonsalkorale WM, Perrey C, Pravica V, et al. Interleukin 10 genotypes in irritable bowel syndrome: evidence for an inflammatory component? Gut 2003;52:91-3. (Pubitemid 36020772)
27. Thiebaut R, Kotti S, Jung C, et al . TNFSF15 polymorphisms are associated with susceptibility to inflammatory bowel disease in a new European cohort. Am J Gastroenterol 2009;104:384-91.
28. Yamazaki K, McGovern D, Ragoussis J, et al. Single nucleotide polymorphisms in TNFSF15 confer susceptibility to Crohn's disease. Hum Mol Genet 2005;14:3499-506. (Pubitemid 41672132)
29. Yang SK, Lim J, Chang HS, et al. Association of TNFSF15 with Crohn's disease in Koreans. Am J Gastroenterol 2008;103:1437-42. (Pubitemid 351813898)
30. Kakuta Y, Ueki N, Kinouchi Y, et al. TNFSF15 transcripts from risk haplotype for Crohn's disease are overexpressed in stimulated T cells. Hum Mol Genet 2009;18:1089-98.
31. Colobran R, Pujol-Borrell R, Armengol MP, et al. The chemokine network. II. On how polymorphisms and alternative splicing increase the number of molecular species and configure intricate patterns of disease susceptibility. Clin Exp Immunol 2007;150:1-12. (Pubitemid 47383308)
32. Vyshkina T, Shugart YY, Birnbaum G, et al . Association of haplotypes in the beta-chemokine locus with multiple sclerosis. Eur J Hum Genet 2005;13:240-7. (Pubitemid 40220569)
33. Sorensen HG, van der Deure WM, Hansen PS, et al. Identification and consequences of polymorphisms in the thyroid hormone receptor alpha and beta genes. Thyroid 2008;18:1087-94.
34. McCarthy MJ, Nievergelt CM, Shekhtman T, et al. Functional genetic variation in the Rev-Erbalpha pathway and lithium response in the treatment of bipolar disorder. Genes Brain Behav 2011;10:852-61.
35. Bond BC, Virley DJ, Cairns NJ, et al. The quantification of gene expression in an animal model of brain ischaemia using TaqMan real-time RT-PCR. Brain Res Mol Brain Res 2002;106:101-16. (Pubitemid 35229992)
36. Spiller R, Card T, Mearin F, et al. Incidence and characteristics of Postinfectious IBS (PI-IBS): a multinational internet survey. Gut 2010;59(Suppl III):A32.
37. Tremelling M, Berzuini C, Massey D, et al. Contribution of TNFSF15 gene variants to Crohn's disease susceptibility confirmed in UK population. Inflamm Bowel Dis 2008;14:733-7. (Pubitemid 351898055)
38. Zucchelli M, Camilleri M, Andreasson AN, et al. Association of TNFSF15 polymorphism with irritable bowel syndrome. Gut 2011;60:1671-7.
39. Brydon L, Edwards S, Jia H, et al. Psychological stress activates interleukin-1beta gene expression in human mononuclear cells. Brain Behav Immun 2005;19:540-6. (Pubitemid 41407703)
40. Yamakawa K, Matsunaga M, Isowa T, et al. Transient responses of inflammatory cytokines in acute stress. Biol Psychol 2009;82:25-32.
41. Al-Lamki RS, Wang J, Tolkovsky AM, et al. TL1A both promotes and protects from renal inflammation and injury. J Am Soc Nephrol 2008;19:953-60.
42. Bamias G, Martin C III, Marini M, et al. Expression, localization, and functional activity of TL1A, a novel Th1-polarizing cytokine in inflammatory bowel disease. J Immunol 2003;171:4868-74. (Pubitemid 37310609)
43. Kamada N, Hisamatsu T, Honda H, et al. TL1A produced by lamina propria macrophages induces Th1 and Th17 immune responses in cooperation with IL-23 in patients with Crohn's disease. Inflamm Bowel Dis 2010;16:568-75.
44. Chadwick VS, Chen W, Shu D, et al. Activation of the mucosal immune system in irritable bowel syndrome. Gastroenterology 2002;122:1778-83. (Pubitemid 34651421)
45. Dunlop SP, Jenkins D, Spiller RC. Distinctive clinical, psychological, and histological features of postinfective irritable bowel syndrome. Am J Gastroenterol 2003;98:1578-83. (Pubitemid 36875351)
46. Piche T, Barbara G, Aubert P, et al. Impaired intestinal barrier integrity in the colon of patients with irritable bowel syndrome: involvement of soluble mediators. Gut 2009;58:196-201.
47. Dunlop SP, Hebden J, Campbell E, et al. Abnormal intestinal permeability in subgroups of diarrhea-predominant irritable bowel syndromes. Am J Gastroenterol 2006;101:1288-94. (Pubitemid 43829995)
48. Burgmann T, Clara I, Graff L, et al. The Manitoba Inflammatory Bowel Disease Cohort Study: prolonged symptoms before diagnosis-how much is irritable bowel syndrome? Clin Gastroenterol Hepatol 2006;4:614-20.
49. Villani AC, Lemire M, Thabane M, et al. Genetic risk factors for post-infectious irritable bowel syndrome following a waterborne outbreak of gastroenteritis. Gastroenterology 2010;138:1502-13.